HER2-Positive Breast Cancer Market Share 2022: Global Trends, Key Players, Industry Analysis Report to 2028

The HER2-Positive Breast Cancer Market size is expected to grow at an annual average CAGR of 1% during 2022-2028. Human epidermal growth factor receptor 2 (HER2) is a gene involved in the development of breast cancer. Genes contain the recipes for many of the proteins cells need to stay healthy and function normally. This protein stimulates cancer cell proliferation. About 1 in 5 breast cancer cancer cells have an extra copy of the gene that produces the HER2 protein. Breast cancer that is HER2-positive is more aggressive than other types of breast cancer. Although anticancer drugs do not directly target the HER2 protein, certain regular chemotherapy treatments may be useful to treat HER2-positive breast tumors. Because results significantly influence treatment recommendations and decisions, experts advise testing for the presence of HER2 in all invasive breast cancers. Except as part of clinical trials, HER2 testing is not usually performed for ductal cancer in situ. If breast cancer recurs or expands, cancer cells should be re-examined for HER2 and hormone receptor status, which may change after the original diagnosis.

The following segmentation are covered in this report:

By Application

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Treatment Type

• Chemotherapy
• Targeted Therapy Immunotherapy
• Others

Company Profile

• Roche (Genentech)
• AstraZeneca and
• Daiichi Sankyo
• Celgene
• Eisai
• Puma Biotechnology Novartis
• Macrogenics
• Seattle Genetics
• Jiangsu HengRui Medicine

Scope of the report

The research study analyses the HER2-Positive Breast Cancer Market industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent developments

• Market overview and growth analysis
• Import and export overview
• Volume analysis
• Current market trends and future outlook
• Market opportunistic and attractive investment segment

Geographic coverage

• North america market size and/or volume
• Latin america market size and/or volume
• Europe market size and/or volume
• Asia-pacific market size and/or volume
• Rest of the world market size and/or volume

Key Questions Answered by HER2-Positive Breast Cancer Market Report

• What was the HER2-Positive Breast Cancer Market size in 2020 and 2021; what are the estimated growth trends and market forecast (2022-2028)
• What will be the CAGR of Market during the forecast period (2022-2028)?
• Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
• Which manufacturer/vendor/players in the HER2-Positive Breast Cancer Market was the market leader in 2022?
• Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.